LAB

Standard BioTools Inc. (LAB) | Rumor.io

Standard BioTools

LAB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,740

Bullish sentiment (50-day avg)45%

Price to earnings ratio-3.63

Market capitalization286.6M

Earnings per share-0.13

Dividend yield (TTM)—

Revenue (annual)85.3M

Net income (annual)-74.9M

Social

What share of all stock conversation is about LAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 8

The price of $LAB has dropped from $24 to $12 in a few days, potentially presenting a buying opportunity.
The company is merging with Treeline Bioscience, which may affect its valuation, with some estimates suggesting an implied EV of $725M.
Some analysts believe $LAB will rebound, citing its track record and ability to raise $1.2B, with a near-term valuation of $2+ and a potential bottom in the low to mid $0.80s.

Generated by AI

Sentiment

Of the messages about LAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	11.11% -11.97	33.32% -15.98
Bearish	—	—	88.89% +11.97	66.68% +15.98

Bullish· Mar 1

Standard BioTools Inc. (LAB) is gaining recognition for its achievements in mass cytometry and microfluidics, including beating TMO and others to market with an EUA PCR-based at-home COVID-19 test.
LAB's valuation is undervalued compared to its achievements, with the company's market cap being less than an NFL quarterback's contract, making it a potentially attractive buy.
The stock's recent price movement is likely due to short covering, with the company poised to come back strong with good approval in Europe and the US, potentially leading to a significant price increase.

Bearish· Feb 11

The company's 1Q and 2021 guidance was dramatically lowered, despite the pandemic-driven need for testing.
The company's revenue is expected to decrease, and institutions are selling their positions, which may lead to a further decline in the stock price.
The company's inability to break through the $9-10 price level for an extended period suggests a lack of momentum and potential for further decline.

Generated by AI

Topics

Of the messages about LAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	4.72%
Technical Analysis	—	—	50%	95.22%
Analysts	—	—	0%	0.05%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 23

Standard BioTools Inc. ($LAB) has agreed to sell SomaLogic to Illumina ($ILMN) for up to $425M, marking a loss on the investment made in 2023.
The sale of SomaLogic is expected to provide Standard BioTools with $550M+ in cash, positioning the company to make two to three more strategic acquisitions.
The deal includes a 2% royalty on net revenues from Single SOMAmer commercialization, and near-term payments of $350M will be made to Standard BioTools.

Technical Analysis· Aug 28

The stock has a solid support level at $8, which is a good sign for long-term investors.
The daily chart shows a bullish trend, with a slow and steady climb expected, potentially breaking even and gaining profits by the end of the year.
A close above $8.8 could be a positive indicator, with little resistance expected beyond that point.

Generated by AI

Community

Of the messages about LAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	20.19%
Newcomers	—	—	100%	79.81%

Aug 19

New traders are finding the preset Take Profit and Stop Loss options on $LAB to be a lifesaver, helping to prevent impulsive decisions.
The innovative tools and support offered by $LAB are making trading feel exciting and safe, with a focus on redefining what trading can be.
$LAB's lowest fees and fairer trades are allowing traders to retain profits and grow their portfolios, rather than draining them with high fees.

Generated by AI

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

Standard BioTools Reports Second Quarter 2026 Financial Results

BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.1 million1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-yearMerger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger

1mo agoYahoo Finance

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

1mo agoBarchart.com

Standard Biotools earnings missed by $0.06, revenue fell short of estimates

1mo agoInvesting.com

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today an

2mo agoYahoo Finance

Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences

Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multi

2mo agoYahoo Finance

Also Discussed

Investors talking about LAB also mention

#	Name	Attention
1	SLGC - SomaLogic, Inc.	——
2	Seer, Inc. Class A Common StockSEER	0%0
3	Thermo Fisher Scientific Inc.TMO	0%0
4	SP - SP Plus Corporation	——
5	Abbott LaboratoriesABT	0%-0.03
6	Fulgent Genetics, Inc.FLGT	0%0
7	DNAY - Codex DNA, Inc.	——
8	Red Rock Resorts, Inc.RRR	0%new
9	Co-Diagnostics Inc.CODX	0%+0
10	OPTN - OptiNose, Inc.	——

Standard BioTools Inc.

Healthcare
Medical Devices

Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research. The company provides instrumentation, consumables, assays, software, and services used to study genes, proteins, cellular behavior, and tissue architecture across early discovery, translational, and clinical research workflows. Its product portfolio includes platforms for genomics, single-cell analysis, spatial biology, mass cytometry, and microfluidics, supporting applications in areas such as oncology, immunology, and biomarker discovery. Standard BioTools serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations worldwide. The company focuses on helping researchers generate high-quality, reproducible biological data that can improve understanding of health and disease.

Website

Location

50 Milk Street

Boston, MA, 02109

United States

Social

What share of all stock conversation is about LAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 8

The price of $LAB has dropped from $24 to $12 in a few days, potentially presenting a buying opportunity.
The company is merging with Treeline Bioscience, which may affect its valuation, with some estimates suggesting an implied EV of $725M.
Some analysts believe $LAB will rebound, citing its track record and ability to raise $1.2B, with a near-term valuation of $2+ and a potential bottom in the low to mid $0.80s.

Generated by AI

Sentiment

Of the messages about LAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	11.11% -11.97	33.32% -15.98
Bearish	—	—	88.89% +11.97	66.68% +15.98

Bullish· Mar 1

Standard BioTools Inc. (LAB) is gaining recognition for its achievements in mass cytometry and microfluidics, including beating TMO and others to market with an EUA PCR-based at-home COVID-19 test.
LAB's valuation is undervalued compared to its achievements, with the company's market cap being less than an NFL quarterback's contract, making it a potentially attractive buy.
The stock's recent price movement is likely due to short covering, with the company poised to come back strong with good approval in Europe and the US, potentially leading to a significant price increase.

Bearish· Feb 11

The company's 1Q and 2021 guidance was dramatically lowered, despite the pandemic-driven need for testing.
The company's revenue is expected to decrease, and institutions are selling their positions, which may lead to a further decline in the stock price.
The company's inability to break through the $9-10 price level for an extended period suggests a lack of momentum and potential for further decline.

Generated by AI

Topics

Of the messages about LAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	4.72%
Technical Analysis	—	—	50%	95.22%
Analysts	—	—	0%	0.05%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 23

Standard BioTools Inc. ($LAB) has agreed to sell SomaLogic to Illumina ($ILMN) for up to $425M, marking a loss on the investment made in 2023.
The sale of SomaLogic is expected to provide Standard BioTools with $550M+ in cash, positioning the company to make two to three more strategic acquisitions.
The deal includes a 2% royalty on net revenues from Single SOMAmer commercialization, and near-term payments of $350M will be made to Standard BioTools.

Technical Analysis· Aug 28

The stock has a solid support level at $8, which is a good sign for long-term investors.
The daily chart shows a bullish trend, with a slow and steady climb expected, potentially breaking even and gaining profits by the end of the year.
A close above $8.8 could be a positive indicator, with little resistance expected beyond that point.

Generated by AI

Community

Of the messages about LAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	20.19%
Newcomers	—	—	100%	79.81%

Aug 19

New traders are finding the preset Take Profit and Stop Loss options on $LAB to be a lifesaver, helping to prevent impulsive decisions.
The innovative tools and support offered by $LAB are making trading feel exciting and safe, with a focus on redefining what trading can be.
$LAB's lowest fees and fairer trades are allowing traders to retain profits and grow their portfolios, rather than draining them with high fees.

Generated by AI

Standard BioTools

Social

Jun 8

Sentiment

Bullish· Mar 1

Bearish· Feb 11

Topics

Announcements· Jun 23

Technical Analysis· Aug 28

Community

Aug 19

News

Standard BioTools: Q2 Earnings Snapshot

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard Biotools earnings missed by $0.06, revenue fell short of estimates

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences

Also Discussed

Standard BioTools Inc.

Company Information

Location

News

Standard BioTools: Q2 Earnings Snapshot

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard Biotools earnings missed by $0.06, revenue fell short of estimates

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences

Also Discussed

Social

Jun 8

Sentiment

Bullish· Mar 1

Bearish· Feb 11

Topics

Announcements· Jun 23

Technical Analysis· Aug 28

Community

Aug 19